Pharvaris NV

Peng Lu, President of Pharvaris N.V., reported multiple transactions in common stock on August 11, 2026.

Berndt Modig, Chief Executive Officer and a Director of Pharvaris N.V., sold 2,292 shares of common stock on July 13, 2026 for $34.97 per share.

Peng Lu, Chief Medical Officer of Pharvaris N.V., reported multiple transactions in common stock on July 11, 2026.

Pharvaris N.V. Director Johannes Schikan sold a total of 37,590 shares of common stock across two transactions on June 29 and June 30, 2026, under a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. reports that Chief Early Development Officer Anne Lesage executed a series of stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. executive Anne Lesage reported transactions involving company common stock, including the exercise of stock options and subsequent sales.

General Atlantic entities have collectively adjusted their beneficial ownership of Pharvaris N.V. ordinary shares to 7.6%, as reported in an amended Schedule 13G filing.

LSP V Cooperatieve U.A. and LSP V Management B.V. report a 4.9% stake in Pharvaris N.V. as of June 30, 2026.

Viking Global Investors LP filed an amendment to its Schedule 13G, reporting a 5.6% beneficial ownership stake in Pharvaris N.V. following the retirement of David C. Ott.

Bain Capital Life Sciences entities have disclosed a collective beneficial ownership of 5.1% in Pharvaris N.V., totaling 3,181,275 ordinary shares as of September 30, 2025.

A group of investors led by Venrock Healthcare Capital Partners has reduced its beneficial ownership in Pharvaris N.V. to 3.8% of ordinary shares.